Dinamika pendapatan YoY sajrone rolas wulan kepungkur: Dermata Therapeutics (DRMA)

Logo perusahaan publik Dermata Corp (DRMA)

Dermata Therapeutics (DRMA) does not pay dividends, focusing instead on completing the final tests of its innovative drug EMT-01. The sales dynamics over the last 12 months year-over-year confirm market interest, while 0.00 represents the latest level value. Physicians value the brand for its safe, natural formulations, although patent protection will remain under threat until the FDA approves new ointments.

DRMA Wutah dodolan YoY (TTM) Dermata Therapeutics, Inc. (11.02.2024 - 18.11.2026)

dermatarx.com (DRMA) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Pambiji fundamental perusahaan:Dermata Therapeutics
Sampel barang Dermata Therapeutics

For Dermata Therapeutics (DRMA), the expansion of the DMT310 drug within the dermatology segment makes monitoring the actual rate of market penetration critically important. By analyzing this chart of LTM sales volume changes compared to the previous year, an investor assesses the daily revenue dynamics over a rolling year, which allows for an impartial recording of shifts in business growth phases and prevents overpaying for a fading trend or missing a reversal.